Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Xian-Janssen Pharmaceutical Ltd. |
---|---|
Information provided by: | Xian-Janssen Pharmaceutical Ltd. |
ClinicalTrials.gov Identifier: | NCT00604279 |
The purpose of this study is to demonstrate that paliperidone palmitate and Risperidone LAI(Long acting injection) have comparable effectiveness.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Risperidone LAI |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study |
Official Title: | A Randomized, Open-Label, Parallel Group Comparative Study of Paliperidone Palmitate (50, 100, 150 mg eq) and Risperidone LAI (Long Acting Injection)(25, 37.5, or 50 mg) in Subjects With Schizophrenia |
Estimated Enrollment: | 420 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | January 2009 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
001: Active Comparator |
Drug: Risperidone LAI
25-50 mg im. once every two weeks
|
This is a randomized, open-label, active-controlled, parallel-group, multicenter comparative study in men and women, aged 18 years or older, who meet DSM-IV criteria for acute schizophrenia for at least 1 year, with PANSS total score of 60-120 at screening and baseline.This study comprises a screening period of no more than 7 days and a 13-week open-label treatment period. The primary objective of this study is to demonstrate that paliperidone palmitate and Risperidone LAI have comparable efficacy. The safety and tolerability of paliperidone palmitate will also be assessed.The primary endpoint is the change from baseline to endpoint in the total PANSS score. The change from the baseline score at each visit and at endpoint will be analyzed using an analysis of covariance (ANCOVA) model with factors for treatment and investigator, and baseline PANSS total score as the covariate. The point estimate and 2-sided 95% confidence interval based on ANCOVA will be provided for the difference between Risperidone LAI and paliperidone palmitate in the mean change from baseline in total PANSS score. Non-inferiority of paliperidone palmitate to Risperidone LAI will be concluded if the lower limit of the 2-sided 95% confidence interval exceeds -5.5.
Paliperidone palmitate will be administered 150 mg eq. at baseline,100 mg eq. paliperidone palmitate at Day 8.Flexibly dose paliperidone palmitate on Day 36 (50 or 100 mg eq.) and on Day 64 (50,100,or150 mg eq.).27.5mg Risperidone LAI will be administered at Day 8 and Day 22.Flexibly dose of Risperidone LAI on Day 36 (25 or 37.5 mg) and Day 64 (25, 37.5, or 50 mg).Dose on Day 50 is the same as Day 36,and dose on Day 78 is the same as Day 64.Method of study drug(s) administration (oral, or im).
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Xian-Janssen Pharmaceutical Ltd. ( Senior Clinical Research Manager ) |
Study ID Numbers: | CR013150, R092670PSY3008 |
Study First Received: | January 17, 2008 |
Last Updated: | December 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00604279 |
Health Authority: | China: State Food and Drug Administration |
Schizophrenia |
Schizophrenia Dopamine Mental Disorders Risperidone |
9-hydroxy-risperidone Psychotic Disorders Serotonin Schizophrenia and Disorders with Psychotic Features |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Pharmacologic Actions Serotonin Antagonists Serotonin Agents Therapeutic Uses Dopamine Agents Central Nervous System Agents |